Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis.
Repeated treatment with chimeric anti-CD4 antibody in multiple sclerosis.
复制标题
在多发性硬化症中重复使用嵌合抗 CD4 抗体进行治疗。
DOI：
10.1002/ana.410360210
复制
发表时间：
1994
影响因子：
11.2
通讯作者：
Steinman,L
中科院分区：
文献类型：
--
作者：
Lindsey,JW;Hodgkinson,S;Mehta,R;Mitchell,D;Enzmann,D;Steinman,L
我们用2 - 4剂cM - T412治疗21例多发性硬化症患者，cM - T412是一种针对辅助/诱导T淋巴细胞上发现的CD4抗原的嵌合单克隆抗体。治疗后循环CD4淋巴细胞的平均数量（±标准误差）从基线时的888（±81）个/mm3下降到246（±18）个。最后一次治疗1年后，CD4计数恢复到335（±32）。该抗体对CD8淋巴细胞、B淋巴细胞或其他白细胞无影响。副作用很小。尽管CD4淋巴细胞长期耗竭，但未发生机会性感染。仅有1例患者可能出现过敏反应。大多数患者临床稳定，但少数进展。我们得出结论，cM - T412反复治疗可有效减少循环CD4淋巴细胞的数量，且无限制性副作用。
We treated 21 multiple sclerosis patients with two to four doses of cM‐T412, a chimeric monoclonal antibody against the CD4 antigen found on helper/inducer T lymphocytes. The mean number (± standard error) of circulating CD4 lymphocytes decreased from 888 (± 81) cells/mm3at baseline to 246 (± 18) after treatment. At 1 year after the last treatment, the CD4 count had recovered to only 335 (± 32). The antibody had no effect on CD8 lymphocytes, B lymphocytes, or other leukocytes. Side effects were minimal. Despite the prolonged depletion of CD4 lymphocytes, no opportunistic infections occurred. Only 1 patient had a possible allergic reaction. Most patients were clinically stable, but a few progressed. We conclude that repeated treatment with cM‐T412 is effective in reducing the number of circulating CD4 lymphocytes and has no limiting side effects.